Compare FLXS & PROF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FLXS | PROF |
|---|---|---|
| Founded | 2001 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Home Furnishings | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 290.6M | 263.8M |
| IPO Year | 1995 | 2017 |
| Metric | FLXS | PROF |
|---|---|---|
| Price | $76.40 | $7.25 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $54.00 | $12.00 |
| AVG Volume (30 Days) | 33.9K | ★ 109.4K |
| Earning Date | 04-20-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.41% | N/A |
| EPS Growth | N/A | ★ 25.89 |
| EPS | ★ 3.63 | 0.19 |
| Revenue | ★ $441,073,000.00 | $16,098,000.00 |
| Revenue This Year | $4.51 | $92.40 |
| Revenue Next Year | $4.89 | $64.10 |
| P/E Ratio | ★ $21.44 | $37.95 |
| Revenue Growth | N/A | ★ 50.73 |
| 52 Week Low | $32.65 | $3.92 |
| 52 Week High | $77.99 | $8.95 |
| Indicator | FLXS | PROF |
|---|---|---|
| Relative Strength Index (RSI) | 64.28 | 53.44 |
| Support Level | $68.02 | $7.00 |
| Resistance Level | $77.19 | $7.93 |
| Average True Range (ATR) | 2.60 | 0.39 |
| MACD | -0.12 | 0.01 |
| Stochastic Oscillator | 61.88 | 41.99 |
Flexsteel Industries Inc is a United States-based company that manufactures, imports, and markets residential upholstered wooden furniture products. Its product offerings include sofas, loveseats, chairs, rockers, desks, tables, convertible bedding units, and bedroom furniture. The company's products are intended for use in home, office, hotel, healthcare, and other contract applications. A featured component in the company's upholstered furniture is the durable Blue Steel Spring. It operates in the business segment of Furniture products. The company's furniture products business involves the distribution of manufactured and imported products for residential markets.
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.